Drug intelligence / Profile preview

diethyldithiocarbamate

Development stage
Preclinical
Modality
Small Molecules
Administration
Investigational: Mainly Intravenous And Oral In Preclinical And Clinical Studies
01

Overview

**Diethyldithiocarbamate** is the anionic form of diethyldithiocarbamic acid and is most recognized as the primary metabolite of disulfiram, a drug used in the management of alcohol dependence. It acts as a **chelating agent**, capable of binding soft metal ions and increasing their elimination from tissues in both experimental animals and humans. Diethyldithiocarbamate is used to mobilize toxic metals, has been investigated as an **orphan drug for AIDS**, and studied as an adjunct in various cancer and liver disease research settings. Mechanistically, it is a known **inhibitor of cytochrome P450 2E1** and **nuclear factor kappa-B (NF-κB)**, possessing antioxidant properties and affecting other signaling pathways including those relevant to liver fibrosis. It also exhibits **superoxide dismutase inhibition** and can impact immune cell signaling and response[1][3][5][7][9].

Brand names
Imuthiol
Other names
ditiocarbdiethyl dithiocarbamatediethylcarbamodithioic aciddiethyldithiocarbamic aciddiethyldithiocarbamate iondiethyldithiocarbamate anionDieca
02

Targets

NF-κBMisfolded SOD1CYP2E1

Beyond the preview

Go deeper on diethyldithiocarbamate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on diethyldithiocarbamate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call